1. STUDY OF GLUCOSE-6-PHOSPATE DEHYDROGENASE IN HEALTH NEONATES
Khishigjargal B ; Gereltuya Y ; Gerelmaa N ; Tungalag L ; Gerelmaa Z ; Erdenetuya G
Innovation 2015;9(4):56-58
Glucose-6-phosphatase dehydrogenase (G6PD) deficiency is the most common enzyme deficiency in humans, affecting 400 million people worldwide and a high prevalence in persons of African, Middle Asian countries. The most common clinical manifestations are neonatal jaundice and acute hemolytic anemia, which is caused by the impairment of erythrocyte’s ability to remove harmful oxidative stress triggered by exogenous agents such as drugs, infection, or fava bean ingestion. Neonatal hyperbilirubinemia caused by glucose-6-phosphate dehydrogenase (G6PD) is strongly associated with mortality and long-term neurodevelopmental impairment. Aim:To determine a level of glucose-6-phosphate dehydrogenase in healthy neonates.The 76.5% of all participants (n=205) was assessed 4.36±1.15 Ug/Hb in normal reference range of G6PD other 23.5% (n=63) was 0.96±0.51 Ug/Hb with G6PD deficiency. In the both sex, 51.5% of male 0.88±0.46Ug/Hb (n=33) and 47.6%of female (n=30) 0.97±0.55Ug/Hb was assessed with G6PDdeficiency. Developing Jaundice period in number of 63 neonates with G6PD deficiency, 85.7% of neonates (n=54)was in 24-72 hours, 4% of neonates (n=3) was in 5-7 days and there is no sign of jaundice in 9% (n=6).Therefore neonates with G6PD deficiency, 53.9% (n=34)contiuned jaundice more than two weeks.G6PD deficiency was determined in male neonates (51.5%) more than female(47.6%). The 76.5% of all participants (n=205) was assessed 4.36±1.15 Ug/Hb in normal reference range of G6PD other 23.5% (n=63) of all participants was 0.96±0.51 Ug/Hb with G6PD deficiency. It shows that G6PD might be one potential risk of neonatal jaundice and hyperbilirubinemia in neonates in Mongolia.
2.Evaluation quality control parameters for standardization of Valmedin pellet and its toxicity
Nomingoo S ; Davaadorj D ; Khishigjargal L ; Manbadar D ; Aldarmaa J
Mongolian Medical Sciences 2018;183(1):35-40
Background:
Valerian (Valeriana officinalis) and Hops (Humulus lupus) are famous herbs in throughout world. Both medicinal herbs have been used for insomnia in European, Asian traditional medicine for centuries. Valmedin consists from mixed herb extracts of Valerian and Hops. It possess antidepressant, anti-anxiety effect, and improves sleep efficiency.
Aim :
The aim of this study was to evaluate quality control parameters for standardization of Valmedin pellet and assess toxicity of Valmedin pellet.
Methods:
In the present study pellets was prepared by extrusion-spheronization technique. The pellet size was determined by sieve analysis using sonic separator. The extract of Valmedin formulation was prepared in pellet (dragee). Valmedin pellet was subjected to analysis for physiochemical parameters, phytochemical studies, heavy metals and quality parameters according to Mongolian pharmacopoeia (2002,). The lethal dose at 50% (LD50) was calculated according to Prozorovskii. In the test chronic toxicity was used two doses of the concentrated extract of Valmedin (0.25; 0.5 g/kg) and assessed parameters (ALT, ALP, AST, bilirubin, total protein, TNFα, IL-6).
Result:
First of all, the quality of biological active components and physiochemical parameters of individual herbs including Valerian, Hops and Metha L have been fulfill the basic requirements of standardization herbal medicines. Moisture content of Valmedin pellets was 1.6 ±0.01%. Total tannin and valerenic acid content found to be 0.051±0.05, 0.71±0.02% for a pellet. Levels of heavy metals was within the permissible range of standard.
In the acute toxicity study, the LD50 value of the concentrated extract from Valmedin was 1.56 g/kg (i.p). No significant changes in body weights of treated animals. In the hematological and biochemical analyses of Valmedin in dose of 250 mg/kg has shown no significant change in the levels of ALT, AST, ALP and levels of RBC and WRC counts in blood serum. Valmedin at dose of 500 mg/kg after chronic injection lower sign levels of ALT, ALP enzymes, and total protein compared with the control group I. It increases significantly levels of AST enzyme, glucose in blood serum. By hematological analyses, Valmedin in dose of 500 mg/kg elicited decrease in the level of hematological parameters such as white blood cells and red blood cells count in whole blood. Likewise, treatment of Valmedin in doses of 250 and 500 mg/kg did not induce any change in the levels of TNF and IL-6 cytokines.
Conclusion
Pellets of Valmedin containing Valerian, Hops, and Metha were successfully made achieving degrees of quality, physical stability compatible with the requirements for standardization and formulation.
3.Sand Sauna Treatment Of Chronic Kidney Disease
Javzmaa L ; Khishigjargal S ; Purevdorj G ; Gelegjamts Kh
Journal of Oriental Medicine 2012;3(2):45-45
The main mechanism of sand sauna therapy is lie into heated sand
baths for adults 8 to 20 min and for child 7 to 15 min long, and it is
performed twice a day (morning and afternoon) for 2 or 3 weeks
once a year. Particularly, the sanatorium offers a type of
balneotherapy through the application of thermally warmed sand
and a combination of healthy micro-bioclimate, purity of the natural
environment, and the presence of fresh and healthy local foods to
treat a wide range of medical conditions. The sand sauna treatment
most likely affect the body by means of the sand’s high temperature
and the presence of chemical elements those are biologically
important.
One of the well-experienced health resorts is the Tavan Els kidney
sanatorium. The Tavan Els sanatorium treats patients with the
following signs: fatigue, shortness of breath, bone and back pain,
swelling of the legs, high blood pressure (over 130/80mmHg),
infrequent urination, proteinuria, and blood in the urine. Their goal is
to delay progression of chronic kidney diseases prevent or slow
additional damage to the patient’s kidneys, improve blood
circulation, decrease the use of medicines, and educate patients
about alternative therapies.
Our study investigated effects of sand sauna treatment more
considering some laboratory findings. There conducted totally 720
patients where 429 inpatients and 291 outpatients. This study
selected 150 patients with chronic glomerulonephritis symptoms of
swelling 31%, blood in urine 9%, high blood pressure (Over 130/80
mmHg) 10% and mixed conditions 50%. After the 10 days
treatment, the proteinuria was decreased 52.6%, and blood in urine
decreased 16, 6% from the total number of patients. Hypertension
was decreased 35% of patients from 10 to 20mmHg and 45% of
patients did not changed. A swelling was cleared 51%, 38%
decreased and 3% did not change. 66% of patients down the weight
loss about 2-4kg, and 34% of patients did not change. We observed
typical changes during 15-20 minutes bathing, heart rate increased
from 65±1.3 bpm at rest to 82±2.4 bpm in 45°C hot sand bath. Blood
pressure increased from 132±4.0/82±2.2 mmHg at rest to
139±1.4/81±1.0 at the bathing. Body temperature was increased 1-
2°C during bathing. Because of the equipment limits, we could not
check the urinary sediment, and serum creatinine.
Sand sauna treatment appears to be an effective and useful method
to treat financial and emotional burdens problems of patients with
chronic kidney disease problems that especially for the symptoms of
high blood pressure, cause of swelling, proteinuria, infrequent urine
and blood in urine as well as improvements of well-being.
4.Results of determination of salidroside content in roots and rhizomes of cultivated and natural Rhodiola rosea L
Khishigjargal B ; Lkhaasuren R ; Batdorj D ; Suvdaa T ; Gantogtokh G ; Orkhon N ; Tsetsegmaa S ; Khurelbaatar L
Mongolian Medical Sciences 2021;195(1):51-55
Introduction:
Rhodiola rosea L. (R.rosea) is a popular plant in traditional medicine of the Nordic countries, Eastern
Europe, and Asia. R.rosea plants are successfully cultivated in Mongolia. The Botanical Garden of
Medicinal Plants under the “Monos” Group started to cultivate R. rosea since May 2015.
Objective:
The aim of this research was to study the salidroside contents of R.rosea collected from Zavkhan
and Khuvsgul province, Mongolia, and cultivated in the Botanical Garden of Medicinal Plants, Drug
research Institute, Monos group.
Material and Methods:
The underground parts of wild roseroot plants were collected from April to May 2020 from Jargalant
soum, Khuvsgul province, and Nomrog soum, Zavkhan province, 3-years and 4-years-old cultivated
R.rosea gathered from the Botanical Garden of Medicinal Plants in April 2020. For comparison,
4-year-old Rhodiola grenulata (R. grenulata) was ordered from Shanxi Zhendong Genuine Medicinal
Materials Development Co., Ltd, China, and used for the study. The quantity of the salidroside
constituents of the underground parts were compared and the sourcing of roseroot raw material was
evaluated. Chemical analysis of roots and rhizome of R. Rosea namely the appearance, identification,
moisture, organic impurities, mineral impurities, residue on ignition, water-soluble extractives, fresh
weight of roots, and salidroside content were determined according to the National Pharmacopoeia of
Mongolia (NPhM) 2011. Microbiological analysis was performed in accordance with the requirements
of grade 3b specified in Annex 1 of the Order No. A / 219 of the Minister of Health dated May 30,
2017 to determine the degree of microbiological purity in medicinal products of roots and rhizome
raw materials.
Result:
The content of salidroside, the main biologically active substance of R.rosea plant, was 1.57% in
samples collected from Zavkhan province, 1.45% in samples collected from Khuvsgul province, 1.7%
in samples grown in China and 0.25% for 3-years-old samples and 1.89% for 4-years-old samples grown in the Botanical Garden of Medicinal Plants, Monos group, Mongolia. In addition, these raw
materials meet the general requirements for plant raw materials and microbiological parameters.
Conclusion
Samples of underground parts of R.rosea cultivated for 4 years in the Botanical Garden of Medicinal
Plants have the highest content (1.89%) of the salidrosde. Therefore, it is suggested that the roots
and rhizomes of R.rosea planted in the future can be standardized and used as a raw materials for
medicines.